Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation
© Son et al.; licensee BioMed Central Ltd. 2014
Received: 20 July 2013
Accepted: 6 December 2013
Published: 10 February 2014
The overexpression of histone deacetylase (HDAC) and a subsequent decrease in the acetylation levels of nuclear histones are frequently observed in cancer cells. Generally it was accepted that the deacetylation of histones suppressed expression of the attached genes. Therefore, it has been suggested that HDAC might contribute to the survival of cancer cells by altering the NKG2D ligands transcripts. By the way, the translational regulation of NKG2D ligands remaines unclear in cancer cells. It appears the modulation of this unclear mechanism could enhance NKG2D ligand expressions and the susceptibility of cancer cells to NK cells. Previously, it was reported that irradiation can increase the surface expressions of NKG2D ligands on several cancer cell types without increasing the levels of NKG2D ligand transcripts via ataxia telangiectasia mutated and ataxia telangiectasia and Rad3 related (ATM-ATR) pathway, and suggested that radiation therapy might be used to increase the translation of NKG2D ligands.
Two NSCLC cell lines, that is, A549 and NCI-H23 cells, were used to investigate the combined effects of ionizing radiation and HDAC inhibitors on the expressions of five NKG2D ligands. The mRNA expressions of the NKG2D ligands were quantitated by multiplex reverse transcription-PCR. Surface protein expressions were measured by flow cytometry, and the susceptibilities of cancer cells to NK cells were assayed by time-resolved fluorometry using the DELFIA® EuTDA cytotoxicity kit and by flow cytometry.
The expressions of NKG2D ligands were found to be regulated at the transcription and translation levels. Ionizing radiation and HDAC inhibitors in combination synergistically increased the expressions of NKG2D ligands. Furthermore, treatment with ATM-ATR inhibitors efficiently blocked the increased translations of NKG2D ligands induced by ionizing radiation but did not block the increased ligand translations induced by HDAC inhibitors. The study confirms that increased NKG2D ligand levels by ionizing radiation and HDAC inhibitors could synergistically enhance the susceptibilities of cancer cells to NK-92 cells.
This study suggests that the expressions of NKG2D ligands are regulated in a complex manner at the multilevel of gene expression, and that their expressions can be induced by combinatorial treatments in lung cancer cells.
It is well known NK cells play a role in immune surveillance for cancer  and that their anticancer immunity is controlled by a balance of activating and inhibitory signals . NKG2D is a well characterized immunoreceptor which mediates activating signals on NK cells and T cell subsets, such as, CD8+ and γδT lymphocytes . In humans, eight distinct NKG2D ligands, including MHC class I chain-related gene A/B(MICA/B) and UL16-binding protein 1–6 (ULBP1-6 or RAET1I,H,N,E,G and L), have been described . Furthermore, the induction of NKG2D ligands by several methods, including treatment with anti-cancer drugs, ionizing radiation, heat shock, or proteasomal inhibition, has been proposed as a strategy for eliciting anti-cancer immunity [5–8]. Radiotherapy is a widely used modality to treat cancer; it causes double-strand DNA breaks, and thus, induces cancer cell death. Although it has been reported that ionizing radiation can induce NKG2D ligands on cancer cells by activating the ATM-ATR pathway , the precise regulatory mechanism involved is unclear. Of the recently developed anti-cancer agents, HDAC inhibitors have been investigated in treatment of cancers, and it has been reported that several HDAC inhibitors, including suberoylanilide hydroxamic acid (SAHA), tricostatin A (TSA), valproic acid, and PCI-24781, enhance the radiosensitivities of cancer cells [10–13]. Because HDAC inhibitors are known potent inducers of NKG2D ligands on many cancer cells [14, 15], it is possible that the induced NKG2D ligands could overcome immune tolerance and make cancer cells sensitive to NK-cell mediated cytotoxicity. Accordingly, we investigated whether ionizing radiation in combination with HDAC inhibitor treatment increases the expressions of NKG2D ligands, and ATM-ATR signaling is involved in this process, and this expressional increases enhances the susceptibility of cancer cell to NK cells.
Materials and methods
Cell lines and reagents
Two human non-small cell lung cancer cell lines, A549 and NCI-H23, were used in this study, and were obtained from the Korean Cell Line Bank (Seoul, Korea). These cell lines were maintained in RPMI media supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY), 2 mM L-glutamine, 100 μg/ml streptomycin, and 100 U/ml penicillin. The NK-92 cell line was obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in alpha-Minimum Essential Modified medium supplemented with 12.5% (v/v) fetal bovine serum, 12.5% (v/v) horse serum, 2 mM L-glutamine,0.1 mM 2-mercaptoethanol, 200 U/mL of recombinant human interleukin-2, 100 μg/mL streptomycin, and 100U/mL penicillin. All cells were cultured at 37°C in a humidified atmosphere containing 5% CO2.Three HDAC inhibitors, apicidin, suberoylanilide hydroxamic acid (SAHA; vorinostat) and tricostatin A (TSA), two ATM-ATR inhibitors, caffeine, and KU-55933, cycloheximide (CHX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). To irradiate cancer cells, we used a ClinaciX Linear Accelerator (Varian Medical Systems, Inc. Palo Alto, CA, USA) with the assistance of Dr. Jiho Nam (Pusan National University Yangsan Hospital).
Total RNA extraction and Multiplex Reverse Transcription (RT)-PCR
Total RNA extraction and RT-PCR were performed as previously described . Briefly, total RNA was extracted from cells using the RNeasy® Mini Kit (Qiagen GmbH, Germany). One microgram of extracted total RNA was used to synthesize cDNA using 100 pmol of random primers (Takara, Japan) and 100 U of M-MLV reverse transcriptase (Promega Co., Fitchburg, Wisconsin, USA). The resulting cDNA was used as template for PCR, which was conducted using the QIAGEN® Multiplex PCR Kit (Qiagen GmbH). Seven pairs of primer sets were used to investigate the expressions of the ribosomal protein L19 (RPL19), MICA, MICB, ULBP1-3, and β-actin (ACTB) genes. ACTB and RPL19 were used as a loading control and a degradation marker, respectively. PCR products were stained by ethidium bromide and separated by 2.0% agarose gel electrophoresis, and quantified using image analyzing software (Quantity One; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
To determine the surface expressions of NKG2D ligands on cancer cells, the cells were incubated with mouse anti-MICA, anti-MICB, anti-ULBP1-3 (R&D systems, Minneapolis, MN, USA), anti-HLA-ABC (Clone W6/32, Serotec, Oxford, UK) or the corresponding isotype controls at 10 μg/ml and then incubated with goat anti-mouse-PE conjugated (BD Pharmingen Inc., San Diego, CA., USA). The analysis was performed on a FACS Sort® (Becton Dickinson, Mountain View, CA., USA) using Cell Quest software (Becton Dickinson), and cell surface expressions were quantified using mean fluorescence intensities (MFIs). Relative expression ratios were calculated by dividing treated sample MFI by untreated sample MFI without subtracting the MFI of the appropriate isotype control.
NK cell-mediated cytotoxicity assay using time-resolved fluorometry
NK cell-mediated cytotoxicity was determined using the DELFIA® EuTDA Cytotoxicity Reagents (PerkinElmer Life Sciences, Waltham, MA, USA), as described previously . Briefly, target cells (1X106 cells/ml) were incubated with freshly prepared 10 μM BATDA (a fluorescence enhancing ligand) in 2 ml of culture medium for 30 min at 37°C, and washed. Next, 100 μl of BATDA-labeled target cells (5,000 cells) were transferred into a round-bottom sterile plate and co-cultured with NK-92 cells for 2 hours at effector/target ratios ranging from 2.5:1 to 10:1. After incubation, 20 μl of supernatant from each well was transferred to the wells of flat-bottom 96 well plates. 180 μl of europium (Eu) solution was then added to form highly fluorescent and stable chelates (EuTDA), and the fluorescences of these chelates were measured by time-resolved fluorometry (Victor3, PerkinElmer). The percent of specific release was calculated using (experimental release – spontaneous release)/(maximum release – spontaneous release) X 100(%). In blocking experiments, blocking anti-NKG2D mAb (R&D Systems) was pre-added to suspensions of NK-92 cells and incubated for 30 min prior to co-cultured with target cells. All experiments were performed in triplicate.
NK cell-mediated cytotoxicity assay by flow cytometry
Fresh NK cells were obtained from normal healthy donors with informed consent in accordance with the Declaration of Helsinki. Target cells (1X105 cells/ml) were stained using the Vybrant® carboxyfluorescein diacetate, succinimidyl ester (CFSE) Cell Tracer Kit (Invitrogen, Eugene, OR, USA) and incubated with NK-92 cells or freshly isolated NK cells at selected effector/target ratios for 2 hours in 5 ml round-bottomed tubes. These co-cultured target cells and NK cells were then stained with 1 μg/ml propidium iodide (Sigma-Aldrich). The assay was performed on FACS Sort® (Becton Dickinson) by acquiring 3,000 target cells. The percent if specific release was calculated by the number of PI+&CFSE+ cells/3,000 X 100 (%). All experiments were performed in triplicate.
To evaluate alterations in gene expression, the gene expressions in treated cells were divided by those in untreated controls (mean fold) and standard errors (SE) were calculated. To compare groups, we used the paired Student’s t-test. Statistical significance was accepted for p values < 0.05.
HDAC inhibitors increase the mRNA expressions of NKG2D ligands but ionizing radiation minimally alters these expressions in A549 cells
Combination of HDAC inhibitors and ionizing radiation prominently increases the surface expressions of NKG2D ligands
The susceptibility of A549 cells to NK cells is synergistically increased by HDAC inhibitors treatment and ionizing radiation in combination
Single use of ATM-ATR inhibitors do not significantly change the expressions of NKG2D ligands at the mRNA level
ATM-ATR inhibitors block the inductions of surface proteins of NKG2D ligands by ionizing radiation but not their inductions by TSA
Protein synthesis inhibitor efficiently suppressed the inductions of NKG2D ligands by TSA
NK cells are remarkably cytotoxic to many different cancer cells in vitro and in vivo. Moreover, NK cell cytotoxicity is controlled by a signaling balance involving the activations and inhibitions of cell surface receptors. Accordingly, the inductions of NKG2Dligands, which are activating ligands in cancer cells, may provide an attractive means of promoting cancer cell recognition by NK cells . It is generally accepted that NKG2D surface protein expressions are restricted in normal cells despite of presence of their transcripts . In our previous experiments, the mRNA levels and surface protein expressions of NKG2D levels were often discordant. In fact, some cancer cells exhibited increased NKG2D ligand surface expressions but no change in mRNA levels after irradiation, which suggests the expressions of NKG2D ligands are strictly regulated at transcriptional and post-transcriptional levels.
A variety of stresses, such as, heat shock and exposure to hydrogen peroxide, DNA damaging agents, or viral or bacterial infection can increase the expressions of MICA/B [8, 9, 21, 22], although the mechanisms involved remain unclear. Recently, it was reported that chromatin remodeling agents, such as, inhibitors of DNA methyltransferase or nuclear histone deacetylase increase the expressions of many proapoptotic or tumor suppressor genes, and thus can induce the growth arrest, differentiation, and apoptosis of cancer cells [23–25]. In addition, the expressions of NKG2D ligands have been reported to be upregulated at the transcription level in some cancer cells [14, 15, 26]. On the other hand, DNA damaging agents usually increase the surface expressions of NKG2D ligands at post-transcriptional level in macrophage through ATM-ATR signaling . Therefore, to further increase the expression of NKG2D ligands in cancer cells, we co-treated cells with ionizing radiation and HDAC inhibitors. We presumed that HDAC inhibitors increase the transcription and ionizing radiation increases the translation of NKG2D ligands via different mechanisms.
The lung adenocarcinoma cell line A549 is resistant to ionizing radiation and to cell-mediated killing [27, 28]. In the present study, we found that ionizing radiation did not significantly increase NKG2D ligand transcript expression in this cell line, but it did increase their protein levels. On the other hand, ionizing radiation significantly increased the expressions of NKG2D ligands at the mRNA and protein levels in NCI-H23 cells (a radiosensitive lung adenocarcinoma cell line). Although we did not investigate the reason for the different responses to ionizing radiation of these two lung cancer cells, it has been shown that they exhibit different p53 activities . Accordingly, our findings suggest that ionizing radiation and HDAC inhibitor co-treatment increase NKG2D ligand expression and enhance the susceptibility of cancer cells to NK-92 cells and freshly isolated NK cells (Figure 3 and Additional file 1). To examine the effects of ionizing radiation and of HDAC inhibitor treatment separately, we inhibited ATM-ATR signaling, which is activated by ionizing radiation and increased the NKG2D ligand expression . We choose two ATM-ATR inhibitors, that is, caffeine and KU-55933, and pretreated cancer cells with these inhibitors prior to administering ionizing radiation or HDAC inhibitors. ATM-ATR inhibitors effectively blocked the induction of NKG2D ligands by ionizing radiation. However, not by HDAC inhibitors except MICA. These findings show that ionizing radiation and HDAC inhibitors differentially affect the ATM-ATR pathway and NKG2D ligand expression. More specifically, caffeine suppressed the expression of MICA at the surface protein level (Figure 5), and although the mechanism of MICA down-regulation by caffeine is not known, it has been reported that MICA transcription is reduced via the inhibitions of PI3K and PKC, which regulators of MICA transcription [17, 30] and caffeine might affect the PI3K and PKC activities. CHX (an inhibitor of protein synthesis) treatment effectively blocked NKG2D ligand induction by HDAC inhibitors. We are of the opinion that ATM-ATR signaling probably does not increase the protein synthesis of NKG2D ligands but rather promotes their translation at a prior step of protein synthesis.
In previous studies, post-transcriptional and -translational regulations were found to be involved in the control of the surface protein levels of NKG2D ligands, and discrepancies between the transcription and surface NKG2D expressions of ligands have often been described [31–33]. We found that co-treatment with ionizing radiation and HDAC inhibitors further increases NKG2D ligand expressions via independent mechanisms in lung cancer cells. BecauseA549 cells did not response to ionizing radiation with respect to the transcriptions of NKG2D ligands and these cells were essentially less susceptible to NK cells, it would appear in this cell-line that by ionizing radiation in the inductions of the surface protein expressions of NKG2D ligands were limited. Although radioresistant lung cancer cells, such as, A549 cells, survive even high-doses irradiation, it appears that co-treatment with ionizing radiation and HDAC inhibitors might be helpful.
This study suggests NKG2D ligands are regulated in a complex, multi-level manner and that they can be induced by ionizing radiation plus HDAC inhibitors in lung cancer cells. We believe that such combination therapies offer an attractive means of improving the efficacy of NK cell-based cancer immunotherapy in patients with radioresistant cancer.
Co-first authors: Cheol-Hun Son and Jin-Hee Keum.
This research was supported by the National R&D Program through the Dong-nam Institute of Radiological & Medical Sciences (DIRAMS) funded by the Ministry of Education, Science and Technology (code: 50590-2013) and the National Research Foundation of Korea (NRF) grant funded by the Korea government(MSIP) (2005-0049416), and Pusan National University Research Grant, 2010, Korea.
- Schmitt C, Ghazi B, Bensussan A: NK cells and surveillance in humans. Reprod Biomed Online 2008, 16: 192-201. 10.1016/S1472-6483(10)60574-3View ArticlePubMedGoogle Scholar
- Lanier LL: NK cell recognition. Annu Rev Immunol 2005, 23: 225-274. 10.1146/annurev.immunol.23.021704.115526View ArticlePubMedGoogle Scholar
- Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285: 727-729. 10.1126/science.285.5428.727View ArticlePubMedGoogle Scholar
- Champsaur M, Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010, 235: 267-285.PubMed CentralView ArticlePubMedGoogle Scholar
- Venkataraman GM, Suciu D, Groh V, Boss JM, Spies T: Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007, 178: 961-969.View ArticlePubMedGoogle Scholar
- Vales-Gomez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT: Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res 2008, 68: 1546-1554. 10.1158/0008-5472.CAN-07-2973View ArticlePubMedGoogle Scholar
- Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT: Proteasome regulation of ULBP1 transcription. J Immunol 2009, 182: 6600-6609. 10.4049/jimmunol.0801214PubMed CentralView ArticlePubMedGoogle Scholar
- Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, Chung BS, Kim SH, Kang CD: Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006, 38: 474-484. 10.1038/emm.2006.56View ArticlePubMedGoogle Scholar
- Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436: 1186-1190. 10.1038/nature03884PubMed CentralView ArticlePubMedGoogle Scholar
- Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM: Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005, 62: 223-229. 10.1016/j.ijrobp.2004.12.088View ArticlePubMedGoogle Scholar
- Yu J, Mi J, Wang Y, Wang A, Tian X: Regulation of radiosensitivity by HDAC inhibitor trichostatin A in the human cervical carcinoma cell line Hela. Eur J Gynaecol Oncol 2012, 33: 285-290.PubMedGoogle Scholar
- Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura H, et al.: Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol 2012, 40: 2140-2146.PubMedGoogle Scholar
- Banuelos CA, Banath JP, MacPhail SH, Zhao J, Reitsema T, Olive PL: Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res 2007, 13: 6816-6826. 10.1158/1078-0432.CCR-07-1126View ArticlePubMedGoogle Scholar
- Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005, 65: 11136-11145. 10.1158/0008-5472.CAN-05-0599View ArticlePubMedGoogle Scholar
- Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al.: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65: 6321-6329. 10.1158/0008-5472.CAN-04-4252View ArticlePubMedGoogle Scholar
- Park SW, Bae JH, Kim SD, Son YO, Kim JY, Park HJ, Lee CH, Park DY, Lee MK, Chung BS, et al.: Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. Cancer Invest 2007, 25: 299-307. 10.1080/07357900701208824View ArticlePubMedGoogle Scholar
- Bae JH, Kim JY, Kim MJ, Chang SH, Park YS, Son CH, Park SJ, Chung JS, Lee EY, Kim SH, et al.: Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother 2010, 33: 391-401. 10.1097/CJI.0b013e3181d32f22View ArticlePubMedGoogle Scholar
- Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al.: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13: 1050-1059. 10.1038/nm1622View ArticlePubMedGoogle Scholar
- Ljunggren HG, Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7: 329-339. 10.1038/nri2073View ArticlePubMedGoogle Scholar
- Eagle RA, Jafferji I, Barrow AD: Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. Curr Immunol Rev 2009, 5: 22-34. 10.2174/157339509787314369PubMed CentralView ArticlePubMedGoogle Scholar
- Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001, 2: 255-260. 10.1038/85321View ArticlePubMedGoogle Scholar
- Borchers MT, Harris NL, Wesselkamper SC, Vitucci M, Cosman D: NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006, 291: L222-L231. 10.1152/ajplung.00327.2005View ArticlePubMedGoogle Scholar
- Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE: P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000, 83: 817-825. 10.1054/bjoc.2000.1327PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q: Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005, 102: 16090-16095. 10.1073/pnas.0505585102PubMed CentralView ArticlePubMedGoogle Scholar
- Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001, 10: 687-692. 10.1093/hmg/10.7.687View ArticlePubMedGoogle Scholar
- Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S: HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009, 28: 2370-2382. 10.1038/onc.2009.117View ArticlePubMedGoogle Scholar
- Kim W, Youn H, Seong KM, Yang HJ, Yun YJ, Kwon T, Kim YH, Lee JY, Jin YW, Youn B: PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases. Radiat Res 2011, 176: 539-552. 10.1667/RR2609.1View ArticlePubMedGoogle Scholar
- Kim H, Kim SH, Kim MJ, Kim SJ, Park SJ, Chung JS, Bae JH, Kang CD: EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother 2011, 34: 372-381. 10.1097/CJI.0b013e31821b724aView ArticlePubMedGoogle Scholar
- Tetsuo M, Tomoko O, Shigeo S, Mikiko M, Yoshikazu S, Kanami Y, Jun-ichi H, Mitsuhiro T, Tetsuya M, Yuichi I, Yo K, Hiroshi T, Takao Y, Takashi T: p53-Defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005, 97: 765-777. 10.1093/jnci/dji133View ArticleGoogle Scholar
- Bae JH, Kim SJ, Kim MJ, Oh SO, Chung JS, Kim SH, Kang CD: Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci 2012, 103: 7-16. 10.1111/j.1349-7006.2011.02109.xView ArticlePubMedGoogle Scholar
- Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996, 93: 12445-12450. 10.1073/pnas.93.22.12445PubMed CentralView ArticlePubMedGoogle Scholar
- Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW: Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 2006, 67: 170-182. 10.1016/j.humimm.2006.02.010View ArticlePubMedGoogle Scholar
- Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA, Zwirner NW: Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 2008, 180: 4606-4614.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.